Malignant Gliomas Biorepository Core

与所涉疾病相关的可靠模型系统是实现发展的关键资产 安全有效的治疗方法。它与胶质母细胞瘤尤其相关，因为这种肿瘤由 患者体内多种类型的肿瘤细胞异质性。最近的研究发现，应用 球体培养使我们能够保持亲本的原始表型和遗传特征。 肿瘤。Core C将利用其目前的服务从以下来源收集更多的胶质母细胞瘤球体(GSS 受影响的患者并发现这些GSS的表型和基因特征特别 与目标2中详细描述的每个项目相关。具体地说，我们将从外科手术中建立球体培养 并进行体内致瘤性测试，以确定我们的样本是否能够概括 患者肿瘤的组织病理学检查。我们还计划为所有人持续提供这些服务 自向每个项目转移具有特征的一般社会保障以来的五年赠款可能需要重新确定其特征。 因此，这一核心将为所有4个项目提供必不可少的服务。这个核心作为核心的意义 生物仓库将消除项目之间的变异性，确保所有项目使用相同的GSS进行 拟议中的实验。

A reliable model system that is relevant to the disease in question is a critical asset to achieve development of safe and effective therapeutics. It is in particular relevant for glioblastoma, since this tumor is composed of heterogeneous multiple types of tumor cells in patients. Recent studies identified that application of the spheroid cultures enables us to maintain the original phenotypic and genetic characteristics of the parental tumors. Core C will utilize its current services to collect additional glioblastoma spheroids (GSs) from affected patients and uncover the phenotypic and genotypic characteristics of these GSs are particularly relevant to each project as detailed in aim 2. Specifically, we will establish spheroid cultures from surgical specimens and perform in vivo tumorigenicity assay to determine if our samples are able to recapitulate patients' tumors histopathologically. We also would plan to provide these services on an ongoing basis for all five years of the grant since characterized GSs transferred to each project may require re-characterization. As such, this Core will provide services essential to all 4 projects. Significance of this Core as a central biorepository will eliminate variability amongst the projects, ensuring that all projects utilize the same GSs for the proposed experiments.